These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30638612)

  • 21. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
    Seki M; Suzuki S
    Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
    Pan PC; Haggiagi A
    Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
    Chen JH; Lee KY; Hu CJ; Chung CC
    Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
    Soman B; Dias MC; Rizvi SAJ; Kardos A
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
    Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
    Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(4):263b. PubMed ID: 29176295
    [No Abstract]   [Full Text] [Related]  

  • 34. Neuromuscular complications of immune checkpoint inhibitors.
    Psimaras D
    Presse Med; 2018; 47(11-12 Pt 2):e253-e259. PubMed ID: 30413332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis.
    Guidon AC
    Continuum (Minneap Minn); 2019 Dec; 25(6):1785-1806. PubMed ID: 31794471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
    Saygin D; Ghosh N; Reid P
    J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
    Hundsberger T; Schreiner B; Roth P
    Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Myasthenia Gravis and Myositis(PD-1 Myopathy)].
    Suzuki S
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):219-223. PubMed ID: 32381950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab.
    Shibuya R; Baba K; Furuta R; Maesaka H; Hirosawa H; Bando T; Oshima A; Onoda H; Nukui T; Dougu N; Joho S; Nakatsuji Y
    Intern Med; 2024 Aug; 63(15):2193-2198. PubMed ID: 38171860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.